Allianz’s SpringWorks Therapeutics SWTX Stock Holding History

Allianz’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,200	Closed	-$38.4K	–	445
2024 Q3	$38.4K	Buy	+1,200	New	+$44.8K	﹤0.01%	352

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Allianz's SWTX Position: Q4 2024 in Review

Allianz sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 1,200 shares — an estimated $38.4K sold.

Allianz first reported a position in SWTX in Q3 2024 and held it in 1 quarter. The position peaked at $38.4K in Q3 2024. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

Allianz reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
Allianz sold 1,200 SpringWorks Therapeutics shares in Q4 2024, an estimated $38.4K.
Allianz first reported a position in SpringWorks Therapeutics in Q3 2024 and held it in 1 quarter.
Allianz's SpringWorks Therapeutics position peaked at $38.4K in Q3 2024.
216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on Allianz's 13F filing for Q4 2024, filed 12 Feb 2025.